Latest Market News

Virgin Australia has reported a robust FY25 performance, surpassing IPO forecasts with strong earnings growth and operational improvements. The airline reaffirms its positive outlook for FY26, underpinned by fleet expansion and ongoing transformation benefits.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Vection Technologies reports its first positive underlying EBITDA alongside a 22% pro-forma revenue increase, driven by major defence contracts and AI integration. The company’s strategic acquisition and sector diversification set the stage for sustainable growth in FY26.

Visionflex Group Limited’s FY25 results highlight a strong transition to a SaaS-driven model, with recurring revenue surging 49% to $1.9 million and total revenue up 33%. Key government and private sector contracts underpin future growth prospects.

Visionflex Group reported a 49% rise in annual recurring revenue to $1.9 million despite a 33% drop in total revenue, driven by a pivot to subscription models and key government and corporate contracts.

Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.